We never compromise
on quality.
Manufacturing Site #1 (Ambernath, India)
Rubicon Research's world-class Ambernath plant is focused on producing pharmaceutical products (Rx as well as over the counter), and supports scale up and commercialization in a range of oral solids.
Our manufacturing facility in Ambernath, Maharashtra, India is 14,250m² for manufacturing of oral solid dosages and more recently, for manufacturing of unit-dose, bi-dose, and multi-dose nasal sprays. The facility is US FDA approved.
| Unit | Year of commencement of operations | Dosage Forms | Major Accreditations/Certifications and Certifying Authorities |
|---|---|---|---|
| Ambernath, Maharashtra, India | 2009 | Oral solid dosages: Tablets, capsules, dispersible tablets, powders, and hard gelatin capsules |
|
| 2024 | Nasal dosages: sprays and drug device combinations |
|
Our manufacturing facility in Ambernath has separate filling lines for unit-dose, bi-dose and multi-dose nasal sprays. This enables us to progress a nasal spray product from its conception to development and up until its commercial supply. We currently have one approved product which is a multi-dose nasal spray that utilizes a drug-device combination.
Major Accreditations/Certifications and Certifying Authorities:
- US FDA
- MHRA UK
- Health Canada
- Food and Drugs Administration, Maharashtra (WHO-GMP accreditation)
- TGA Australia
- Ministry of Health, Cambodia
Manufacturing Site #2 (Satara, India)
Our other manufacturing facility in Satara, Maharashtra, India is 4,050 m² for manufacturing of oral liquid dosages.
Our manufacturing facilities at Ambernath and Satara in India are both US FDA approved.
To request for our equipment list, drop us an email at bd@rubicon.co.in
| Unit | Year of commencement of operations | Dosage Forms | Major Accreditations/Certifications and Certifying Authorities |
|---|---|---|---|
| Satara, Maharashtra, India | 2021 (year of acquisition by the Company) | Oral liquids: Oral syrups, suspensions, and solutions |
|